In this study, we evaluated a combination of MCT1 inhibition and Complex I inhibition, to simultaneously target both the glycolytic and OXPHOS metabolic characteristics of DLBCL tumour cells. Here, SLC16A1 is linked to diffuse large B-cell lymphoma.